Catalog No.
Product Name
Application
Product Information
Citations
-
DP2 Receptor Agonist
13,14-Dihydro-15-keto prostaglandin D2 is a selective agonist of the DP2 receptor, derived from the 15-hydroxyl PGDH metabolic pathway. This compound is known to inhibit ion flux in canine colonic mucosa preparations, thereby impacting various physiological processes. It serves as a valuable tool for research applications exploring inflammation, allergic responses, and other DP2 receptor-mediated functions in biological systems. -
Thromboxane Synthase Inhibitor
Dazoxiben hydrochloride is a potent thromboxane synthase inhibitor that exhibits oral bioavailability. It effectively suppresses thromboxane production, a key factor in platelet aggregation and vascular smooth muscle contraction. This compound is utilized in research focused on cardiovascular diseases and conditions related to thrombosis and inflammation. -
Pulmonary Vasodilator Prodrug
Treprostinil palmitil is a long-acting pulmonary vasodilator prodrug that targets the inhibition of hypoxia-induced pulmonary vasoconstriction. Formulated in lipid nanoparticles, it exhibits sustained lung presence while minimizing systemic exposure. Research applications include the investigation of pulmonary arterial hypertension and interstitial lung disease, as well as the capacity to inhibit pulmonary vascular remodeling induced by Su/Hx challenge in animal models. Additionally, Treprostinil palmitil is associated with cough induction. -
TXA2 Receptor Antagonist
Daltroban is a selective thromboxane A2 (TXA2) receptor antagonist. It enhances intracellular calcium levels in vascular smooth muscle cells, contributing to its pharmacological effects. Research demonstrates that Daltroban offers protective benefits in models of reperfusion injury, making it a valuable tool for studies related to cardiovascular health and vascular smooth muscle function. -
PGD2 Antagonist
BW A868C is a selective and potent competitive antagonist of prostaglandin D2 (PGD2). This hydantoin derivative, structurally related to BW245C, demonstrates high specificity without affecting other prostaglandin receptors, including IP, EP1, EP2, TP, and FP. BW A868C is valuable for research applications involving PGD2 pathways and its role in various physiological and pathological processes. -
EP4 Receptor Antagonist
AAT-008 is a selective and orally active antagonist of the prostaglandin EP4 receptor, exhibiting Ki values of 0.97 nM for recombinant human EP4 and 6.1 nM for recombinant rat EP4. This compound demonstrates significant tumor growth delay in murine models of CT26WT colon tumors when used in conjunction with radiotherapy. AAT-008 is valuable for investigating acute and chronic inflammatory pain, as well as cancer-related research applications. -
EP4 Antagonist
EP4-IN-1 is a selective antagonist of the prostanoid EP4 receptor, primarily involved in modulating inflammatory responses and immune regulation. This compound demonstrates significant potential in the fields of tumor immunology and anti-inflammatory analgesia research. By inhibiting EP4 signaling, EP4-IN-1 may contribute to the development of novel therapeutic strategies for cancer and chronic pain management. -
EP2 Receptor Antagonist
EP2 receptor antagonist-2 (CID891729) is a selective antagonist of the EP2 receptor, effectively inhibiting PGE2-induced receptor activation. This compound also demonstrates the ability to suppress lactate dehydrogenase (LDH) release triggered by N-methyl-D-aspartate (NMDA). It is valuable for research applications focused on inflammatory responses and neuronal excitotoxicity. -
EP2/DP1/IP Agonist
Treprostinil diethanolamine is a potent agonist of the EP2, DP1, and IP receptors, exhibiting Ki values of 3.6 nM for EP2, 4.4 nM for DP1, and 32.1 nM for IP. This compound plays a critical role in elevating cAMP levels, contributing to vascular homeostasis. Treprostinil diethanolamine is particularly effective in inducing vasodilation of human pulmonary arteries, making it a valuable reagent for research in cardiovascular and pulmonary disease pathways. -
EP4 Agonist
11-Deoxy Prostaglandin E2 is a selective agonist of the EP4 receptor, exhibiting an EC50 of 0.66 nM. This analog of prostaglandin E2 plays a significant role in modulating various biological processes. It is valuable for research applications related to bone healing, heart failure, and other conditions associated with receptor activation. -
CRTh2 Antagonist
LAS191859 is a potent and selective antagonist of the CRTh2 receptor, exhibiting an IC50 value of 9.58 nM in human CRTh2 assays. This compound is primarily used in research related to chronic asthma, where it may help elucidate the role of CRTh2 in inflammatory pathways and potential therapeutic strategies. Its oral bioactivity makes it a valuable tool for investigating the modulation of immune responses associated with respiratory conditions. -
Prostacyclin Receptor Antagonist
RO3244794 is a potent and selective antagonist of the prostacyclin receptor (IP receptor), demonstrating a pKi value of 7.7 in human platelets and 6.9 in a recombinant IP receptor system. This compound shows significant analgesic and anti-inflammatory properties, making it a valuable tool for researchers investigating pain mechanisms and inflammatory conditions. Its specificity and efficacy contribute to its potential applications in pharmacological studies related to cardiovascular diseases and other related disorders. -
CRTH2 Antagonist
CAY10471 is a selective antagonist of the prostaglandin D2 receptor CRTH2, demonstrating potent oral bioactivity. It effectively attenuates the progression of tubulointerstitial fibrosis and mitigates chronic contact hypersensitivity in animal models. This compound is valuable for research into inflammatory diseases and potential therapeutic pathways involving the CRTH2 receptor. -
EP2 receptor Agonist
PGN-9856 is a selective agonist of the EP2 receptor, exhibiting high affinity with a pKi of 8.3 or greater. This potent non-prostanoid compound demonstrates significant biological activity, with an EC50 value of 8.5 or higher, making it effective in anti-inflammatory and anti-glaucoma research applications. PGN-9856 serves as a valuable tool for exploring the therapeutic potential of targeting the EP2 receptor in various pharmacological studies. -
NSAID
Alclofenac is a non-steroidal anti-inflammatory drug (NSAID) that acts as a selective inhibitor of prostaglandin H2 synthase. It exhibits significant anti-inflammatory and analgesic properties, making it suitable for studies related to rheumatoid arthritis, degenerative joint disease, and ankylosing spondylitis. This compound is valuable for research into the mechanisms of pain and inflammation pathways. -
Thromboxane Synthase Inhibitor
Furegrelate sodium is a selective thromboxane synthase inhibitor, demonstrating significant inhibition of human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. This compound is being investigated for its potential as an antiplatelet agent, making it a valuable tool for research in cardiovascular diseases and platelet function studies. Its oral availability enhances its applicability in preclinical and clinical settings, contributing to advancements in antiplatelet therapy development. -
EP4 Receptor Antagonist
EP4 receptor antagonist 2 is a tricyclic spiro-based compound that selectively targets the EP4 receptor. It exhibits stable microsomal properties, making it suitable for in vitro studies. This compound is primarily utilized in research focused on inflammation and pain pathways, providing insights into therapeutic interventions for various diseases associated with EP4 receptor activation. -
Vasoconstrictor
U-44069 is a stable analogue of prostaglandin H2 that functions as a potent vasoconstrictor. It effectively induces calcium influx in preglomerular vessels, making it a valuable tool for studying vascular physiology and related signaling pathways. This compound is useful for research applications focused on vascular response and regulation. -
Lower Intraocular Pressure Agent
Bimatoprost grenod (NCX 470) is a second-generation nitric oxide (NO)-donating prostaglandin analogue designed to lower intraocular pressure (IOP). It operates by enhancing uveoscleral outflow through bimatoprost activation while facilitating conventional outflow via NO release. This compound is valuable for research focused on ocular hypertension and glaucoma, making it a significant tool for studying IOP regulation and potential therapeutic interventions. -
PGHS1 Inhibitor
Satigrel is a selective inhibitor of prostaglandin H synthase 1 (PGHS1), primarily targeting platelet aggregation. It effectively inhibits collagen- and arachidonic acid-induced platelet aggregation by blocking thromboxane A2 synthesis. With an IC50 of 0.081 μM for PGHS1 and 5.9 μM for PGHS2, Satigrel also demonstrates inhibitory activity against Type III, Type V, and Type II phosphodiesterases, with IC50 values of 15.7 μM, 39.8 μM, and 62.4 μM, respectively. This compound is valuable for research into platelet function and thrombotic diseases. -
F2α Receptor Antagonist
AS604872 is a potent and selective antagonist of the prostaglandin F2α receptor (FP), exhibiting a Ki of 35 nM in human assays. This compound is known to inhibit uterine contractions and may delay labor, making it a valuable tool for research related to reproductive health and uterine physiology. Its oral bioactivity further supports its utility in in vivo studies. -
PGF2α Metabolite
15-keto-Prostaglandin F2α is a metabolite of Prostaglandin F2α, functioning primarily as an agonist for the prostaglandin F receptor (FP receptor). This compound is essential for understanding the physiological roles of prostaglandin signaling, particularly in the regulation of labor onset and progression. It serves as a valuable tool in research applications exploring reproductive biology and related therapeutic interventions. -
Prostaglandin Receptor
ONO-8713 is a selective antagonist of the prostaglandin E receptor subtype EP1. This compound inhibits EP1 receptor activity, which plays a critical role in various physiological processes, including pain perception and inflammation. ONO-8713 is utilized in research focused on investigating the role of prostaglandin signaling in pathophysiological conditions and developing novel anti-inflammatory therapies. -
Deuterated Nepafenac
Nepafenac-d5 is a deuterated derivative of Nepafenac, a nonsteroidal anti-inflammatory drug that functions primarily as a topical COX-2 inhibitor with an IC50 of 0.12 μM. This compound exhibits minimal COX-1 inhibition (IC50 = 64.3 μM) and possesses prodrug characteristics, allowing it to rapidly convert to the active metabolite Amfenac in ocular tissues. Nepafenac-d5 is employed in research to investigate its efficacy in reducing inflammation and managing pain following ophthalmic procedures, as well as its potential to inhibit uveal melanoma metastasis in preclinical models. -
Endogenous Hormone
Prostaglandin F2α ethanolamide is an ethanolamide that acts on G protein-coupled receptors. This compound has been identified as a potential nociceptive mediator in the spinal cord and plays a role in reproductive physiology, particularly as a luteinizing hormone in sheep. It is useful for research applications exploring pain mechanisms and reproductive hormone signaling pathways. -
Prostaglandin E2 Inhibitor
Thielavin A is a selective inhibitor of prostaglandin E2 biosynthesis, derived from the fungus Thielavia terricola. It specifically targets the conversion of arachidonic acid to prostaglandin H2, thereby disrupting the prostaglandin synthesis pathway. Despite its inhibition of prostaglandin E2, Thielavin A exhibits minimal anti-inflammatory effects upon intravenous or oral administration, making it a valuable tool for studying prostaglandin-related biological processes and inflammation research. -
Isomer
(Z)-ONO 1301 is the isomer of ONO 1301, serving as an important experimental control in research. ONO 1301, a prostaglandin I2 mimetic, functions as a long-acting prostacyclin agonist with thromboxane-synthase inhibitory properties. It has been shown to enhance the production of hepatocyte growth factor (HGF) in multiple cell types and to improve ischemia-induced left ventricular dysfunction in murine, rat, and porcine models. This compound is valuable for studies focused on cardiovascular protection and tissue regeneration. -
Prostaglandin
1a,1b-Dihomo prostaglandin E1 is an analogue of prostaglandin that targets various prostaglandin receptors. This compound exhibits notable biological activities, influencing inflammation, vascular function, and cellular signaling pathways. It is primarily utilized in research applications related to cardiovascular studies, inflammation, and endocrinology, providing insights into prostaglandin-mediated physiological processes. -
Prostaglandin Analogue
Carboprost tromethamine is a synthetic analogue of prostaglandin F2α that primarily targets prostaglandin receptors. It is known for its ability to induce uterine contractions and effectively reduce bleeding during and after childbirth. This compound is commonly utilized in obstetric medicine to manage postpartum hemorrhage and facilitate labor. Its biological activity is critical in ensuring maternal safety and improving clinical outcomes in delivery situations. -
Prostaglandin Receptor
17-Phenyl trinor PGF2α isopropyl ester is a synthetic analog of F-series prostaglandins targeting the FP receptor. It exhibits potent agonistic activity, pivotal for reducing intraocular pressure (IOP), making it relevant in glaucoma research. In comparative studies, this compound has demonstrated significant IOP-lowering effects in animal models, outperforming other analogs while eliciting a pronounced irritant response. Its properties are key in exploring therapeutic options for ocular hypertension. -
PGD2 Analog
15(R)-15-Methyl prostaglandin D2 is a metabolically stable synthetic analog of PGD2 that selectively targets the CRTH2/DP2 receptor. This compound is known for its potent biological activities, including the regulation of eosinophil functions such as CD11b expression, actin polymerization, and chemotaxis, with EC50 values of 1.4, 3.8, and 1.7 nM, respectively. Its efficacy in these activities is significantly greater compared to natural PGD2. Additionally, 15(R)-15-Methyl prostaglandin D2 shows minimal action on the DP1 receptor, making it a valuable tool for research in immunology and inflammation studies. -
TxA2/PGH2 Receptor Antagonist
Ifetroban is an orally active antagonist of the thromboxane A2 (TXA2) and prostaglandin H2 (PGH2) receptors. It exhibits significant antiplatelet activity and effectively inhibits tumor cell migration while leaving cell proliferation unaffected. This compound is applicable in research related to myocardial ischemia, hypertension, stroke, thrombosis, and cardiomyopathy. -
DP2 Antagonist
Pexopiprant is a potent oral antagonist of the prostaglandin D2 receptor 2 (DP2), exhibiting a Ki value of less than 100 nM. This compound is primarily utilized in research related to asthma and other allergic inflammatory responses, where modulation of the DP2 pathway may provide therapeutic insights. Its ability to inhibit DP2 receptor activity positions Pexopiprant as a valuable tool for elucidating the role of prostaglandin signaling in various biological contexts. -
EP2 Agonist
Aganepag isopropyl is an EP2 receptor agonist that selectively stimulates the prostaglandin E2 receptor subtype 2. This compound plays a significant role in modulating inflammatory responses and vascular functions. Its utility in research includes exploring pathways related to pain perception, neuroinflammation, and potentially neuroprotective effects. Aganepag isopropyl serves as a valuable tool for studies investigating the role of EP2 in various physiological and pathological processes. -
NSAID
Droxicam is a non-steroidal anti-inflammatory drug (NSAID) primarily acting as an analgesic by inhibiting prostaglandin E2 (PGE2) synthesis. This pro-drug of Piroxicam exhibits significant anti-inflammatory properties and is noted for its favorable tolerance profile, with minimal mucosal side effects. In preclinical studies, Droxicam has demonstrated a lack of cardiovascular and respiratory effects in feline models, as well as the ability to inhibit peritoneal capillary permeability in murine subjects, making it suitable for various research applications in inflammation and pain. -
EP4 Receptor Antagonist
BGC-20-1531 free base is a selective antagonist of the prostanoid EP4 receptor, exhibiting a pKB of 7.6. This compound demonstrates potent inhibitory activity and is primarily utilized in research related to migraine headache mechanisms and treatments. Its specificity for the EP4 receptor makes it a valuable tool for exploring prostaglandin signaling pathways involved in pain modulation. -
sPLA2 Inhibitor
CAY10590 is a potent inhibitor of secreted phospholipase A2 (sPLA2), serving as a valuable tool for investigating the role of sPLA2 in chronic inflammatory kidney diseases. Its mechanism of action enables the modulation of inflammatory pathways, which is critical for understanding disease mechanisms and potential therapeutic interventions. This compound is applicable in preclinical research aimed at elucidating the involvement of sPLA2 in renal pathologies. -
PTGR2 Inhibitor
HHS-0701 is a potent inhibitor of prostaglandin reductase 2 (PTGR2), functioning as a sulfur-triazole exchange (SuTEx) ligand. This compound effectively blocks the metabolism of the lipid substrate 15-Keto-PGE2 by PTGR2, playing a crucial role in modulating prostaglandin levels. HHS-0701 is valuable for research applications involving inflammation and lipid metabolism, providing insights into the enzymatic regulation of prostaglandins. -
PGI2 Analogue
Taprostene is a synthetic analogue of Prostacyclin (PGI2) with enhanced chemical stability. It demonstrates protective effects on the endothelium and myocardium following acute myocardial ischemia and reperfusion, particularly in feline models. Taprostene's ability to promote cytoprotection while reducing adverse hemodynamic responses makes it a valuable investigational tool in cardiovascular research applications. -
Antithrombotic Agent
Etofylline clofibrate is an antithrombotic agent that primarily interacts with prostaglandin I2 (PGI2) in the vascular intima. This compound exhibits hypolipidemic properties, contributing to its role in lipid metabolism modulation. Its biological activities make it a valuable tool for research in cardiovascular diseases and thrombotic disorders. -
EP4 Antagonists
AMX12006 is a selective EP4 antagonist that exhibits a potent inhibitory effect with an IC50 value of 4.3 nM. This compound demonstrates notable cytotoxic and antitumor activity, making it a valuable tool for research in cancer biology and therapeutic applications targeting the prostaglandin E receptor pathway. Its oral bioavailability enhances its utility in preclinical studies. -
Endogenous Hormone
Prostaglandin F2α serinol amide is a G protein-coupled receptor that targets the endogenous hormone pathway, effectively increasing intracellular calcium levels in human non-small cell lung cancer cells. This compound plays a critical role in various biological processes, including its function as a luteinizing hormone in ovine species and its potential role as a nociceptive mediator within the spinal cord. Its biological activity makes it a valuable tool for research in cancer biology and neurobiology. -
Prostaglandin Receptor
Thromboxane B1 (TXB1) is a prominent member of the thromboxane family and acts primarily on prostaglandin receptors. This eicosanoid plays a critical role in regulating platelet aggregation and vascular tone, making it essential in the study of thrombotic disorders. TXB1 is widely utilized in research applications related to cardiovascular biology and the assessment of vascular responses, contributing to our understanding of various pathophysiological conditions. -
Racemate
(±)5-iPF2α-VI is a racemic isoprostane derived from arachidonic acid, primarily acting as a biomarker for oxidative stress. This compound is important for investigating oxidative damage and lipid peroxidation in biological systems. It serves as a valuable tool in research applications focused on inflammation, cardiovascular diseases, and cellular stress responses. -
TP Receptor Antagonist
TP Receptor Antagonist-3 (compound 51280) is a potent antagonist of the thromboxane A2 receptor (TP), exhibiting an IC50 of 15.7 nM against human TP. This compound is valuable for investigating disease mechanisms in Alzheimer's disease, cardiovascular conditions, and respiratory disorders, as well as cancer research applications. Its ability to selectively inhibit TP receptor signaling makes it an important tool for exploring therapeutic interventions in these areas. -
Luteolytic Agent
Cloprostenol is a synthetic analogue of prostaglandin F2α (PGF2α) that serves as a luteolytic agent. It effectively induces luteolysis, making it valuable for research in reproductive biology and veterinary medicine, particularly in studies involving open-cervix pyometra. This compound is essential for exploring mechanisms of luteal regression and hormonal regulation in various biological contexts. -
EP1 Receptor Antagonist
SC 51089 is a selective antagonist of the prostaglandin E2 EP1 receptor, characterized by binding affinities with Kis of 1.3 μM for EP1, and higher affinities for TP, EP3, and FP receptors, with Kis of 11.2, 17.5, and 61.1 μM, respectively. This compound has demonstrated neuroprotective activity, making it valuable for research applications focused on neuroinflammation and pain signaling pathways. SC 51089 offers potential insights into EP1 receptor-related diseases and therapeutic interventions. -
Antioxidant
Cyanidin is a potent antioxidant and enzyme inhibitor targeting cyclooxygenases PGHS-1 and PGHS-2, with IC50 values of 90 μM and 60 μM, respectively. This compound exhibits significant antioxidant and anti-inflammatory properties, effectively scavenging free radicals, inhibiting lipid peroxidation, and protecting DNA from oxidative damage. Cyanidin is valuable for research into inflammatory diseases and related therapeutic applications. -
Vasodilator
19(R)-HETE is a potent vasodilator that primarily acts on renal arteries. Its biological activity is significant in modulating vascular tone and blood flow, making it a valuable tool for studies related to renal function and hypertension. Researchers can utilize 19(R)-HETE to investigate its effects on vascular smooth muscle relaxation and the underlying signaling pathways involved in renal circulation. -
EP1 Receptor Antagonist
ONO-8711 is a selective competitive antagonist of the EP1 receptor, with Ki values of 0.6 nM for human and 1.7 nM for mouse EP1. This compound has demonstrated significant efficacy in reducing tumor incidence and multiplicity in mouse models of colon, breast, and oral cancers. ONO-8711 is valuable for research applications related to cancer biology and the modulation of EP1 receptor signaling pathways.
